Cargando…
An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells
Despite great advances in the treatment of acute leukemia, a renaissance of current chemotherapy needs to be improved. The present study elucidates the underlying mechanism of a new synthetic quinoline derivative, MPT0B392 (B392) against acute leukemia and its potential anticancer effect in drug res...
Autores principales: | Chao, Min-Wu, Huang, Han-Li, HuangFu, Wei-Chun, Hsu, Kai-Cheng, Liu, Yi-Min, Wu, Yi-Wen, Lin, Chao-Feng, Chen, Yi-Lin, Lai, Mei-Jung, Lee, Hsueh-Yun, Liou, Jing-Ping, Teng, Che-Ming, Yang, Chia-Ron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438607/ https://www.ncbi.nlm.nih.gov/pubmed/28186963 http://dx.doi.org/10.18632/oncotarget.15115 |
Ejemplares similares
-
MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer
por: Huang, Han-Li, et al.
Publicado: (2016) -
A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo
por: Wu, Yi-Wen, et al.
Publicado: (2021) -
The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells
por: Tu, Huang-Ju, et al.
Publicado: (2018) -
A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo
por: Wu, Yi-Wen, et al.
Publicado: (2018) -
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
por: Chao, Min-Wu, et al.
Publicado: (2019)